HYDERABAD, India, Dec 24 () - Global pharma giants Eli Lilly and Novo Nordisk are scrambling to cement their lead in India's booming obesity drug market before cheaper generic versions hit shelves in March next year. Novo's strategy emphasizes price cuts and accelerated launches, while Lilly's products benefitted from hitting the market early.

Robert Hays, an industrial electronics salesman in Arkansas, thought he’d purchased conventional medical insurance. So did Essie Nath, 67, a retired cafeteria worker in Wyoming. So did Martin Liz, 47, a Key West chef. Each enrolled in the kind of private health insurance that Trump administration officials have promoted as an alternative to plans sold under Obamacare.Subscribe to The Post Most newsletter for the most important and interesting stories from The Washington Post. The difference betw

Picking the right versatile installment arrangement is urgent for private ventures looking for effectiveness and consumer loyalty. With various choices accessible,